Better-than-expected 3Q at 'two businesses' Pfizer
This article was originally published in Scrip
Executive Summary
Like its European peer Novartis, Pfizer has reported 3Q results that beat analyst expectations. A tough quarter had been anticipated, and while revenue and earnings per share both fell by 2% compared with the same period last year, the drops were not as sharp as had been forecast. Revenues for the three months ended 30 September were $12.4bn with EPS of $0.57. Consensus estimates had put revenues at $12.25bn with EPS of $0.55.